Literature DB >> 19692477

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Elin S Gray1, Maphuti C Madiga, Penny L Moore, Koleka Mlisana, Salim S Abdool Karim, James M Binley, George M Shaw, John R Mascola, Lynn Morris.   

Abstract

We identified three cross-neutralizing plasma samples with high-titer anti-membrane proximal external region (MPER) peptide binding antibodies from among 156 chronically human immunodeficiency virus type 1-infected individuals. In order to establish if these antibodies were directly responsible for the observed neutralization breadth, we used MPER-coated magnetic beads to deplete plasmas of these specific antibodies. Depletion of anti-MPER antibodies from BB34, CAP206, and SAC21 resulted in 77%, 68%, and 46% decreases, respectively, in the number of viruses neutralized. Antibodies eluted from the beads showed neutralization profiles similar to those of the original plasmas, with potencies comparable to those of the known anti-MPER monoclonal antibodies (MAbs), 4E10, 2F5, and Z13e1. The anti-MPER neutralizing antibodies in BB34 were present in the immunoglobulin G3 subclass-enriched fraction. Alanine scanning of the MPER showed that the antibodies from these three plasmas had specificities distinct from those of the known MAbs, requiring one to three crucial residues at positions 670, 673, and 674. These data demonstrate the existence of MPER-specific cross-neutralizing antibodies in plasma, although the ability to elicit such potent antiviral antibodies during natural infection appears to be rare. Nevertheless, the identification of three novel antibody specificities within the MPER supports its further study as a promising target for vaccine design.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692477      PMCID: PMC2772769          DOI: 10.1128/JVI.01359-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1.

Authors:  Helen Donners; Betty Willems; Els Beirnaert; Robert Colebunders; David Davis; Guido van der Groen
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

2.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

3.  Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells.

Authors:  R Kunert; W Steinfellner; M Purtscher; A Assadian; H Katinger
Journal:  Biotechnol Bioeng       Date:  2000-01-05       Impact factor: 4.530

4.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

5.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

7.  4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Authors:  Elin S Gray; Penny L Moore; Frederic Bibollet-Ruche; Hui Li; Julie M Decker; Tammy Meyers; George M Shaw; Lynn Morris
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

8.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

9.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

10.  Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study.

Authors:  Francois van Loggerenberg; Koleka Mlisana; Carolyn Williamson; Sara C Auld; Lynn Morris; Clive M Gray; Quarraisha Abdool Karim; Anneke Grobler; Nomampondo Barnabas; Itua Iriogbe; Salim S Abdool Karim
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

View more
  71 in total

1.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

2.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 4.  Is developing an HIV-1 vaccine possible?

Authors:  Barton F Haynes; Hua-Xin Liao; Georgia D Tomaras
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV.

Authors:  Anne-Sophie Dugast; Kelly Arnold; Giuseppe Lofano; Sarah Moore; Michelle Hoffner; Melissa Simek; Pascal Poignard; Michael Seaman; Todd J Suscovich; Florencia Pereyra; Bruce D Walker; Doug Lauffenburger; Douglas S Kwon; Brandon F Keele; Galit Alter
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

6.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 7.  Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Authors:  Weizao Chen; Tianlei Ying; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

8.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

9.  Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

Authors:  S Gnanakaran; Marcus G Daniels; Tanmoy Bhattacharya; Alan S Lapedes; Anurag Sethi; Ming Li; Haili Tang; Kelli Greene; Hongmei Gao; Barton F Haynes; Myron S Cohen; George M Shaw; Michael S Seaman; Amit Kumar; Feng Gao; David C Montefiori; Bette Korber
Journal:  PLoS Comput Biol       Date:  2010-10-07       Impact factor: 4.475

10.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Authors:  Tessa Dieltjens; Leo Heyndrickx; Betty Willems; Elin Gray; Lies Van Nieuwenhove; Katrijn Grupping; Guido Vanham; Wouter Janssens
Journal:  Retrovirology       Date:  2009-12-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.